


Amendments to the Claims:

This listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

5, 6, 8, 9, 18-21, 25, 27-29, 50-72: (Cancelled)

73. (New): A compound of Formula I:




Formula I

wherein W, X, Y, and Z are C-R<sub>1</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>1</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is




R<sub>1</sub> and R<sub>2</sub> are substituted phenyl.

74. A pharmaceutically acceptable salt of the compound of claim 73.

75. A pharmaceutical composition comprising the compound of claim 73 and a pharmaceutically acceptable carrier.

76. (New): A compound having the structure and meanings for R as indicated:

-3-



wherein R is selected from the group consisting of:

- a) 4-BrPh;
- b) 4-COOEt-Ph;
- c) 4-CF<sub>3</sub>Ph;
- d) 3-Me-Ph;
- e) 3-COOEt-Ph;
- f) 3-COOtBu-Ph;
- g) 3-COOH-Ph;
- h) 4-MeO-Ph;
- i) 3-MeO-Ph; and
- j) 2-MeO-Ph.

77. (New): A compound selected from:

Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-;

Benzoic acid, 3-[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-ethyl ester;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-methoxy-phenyl)-;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxy-phenyl)-;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(2-methoxy-phenyl)-;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-tri-

-4-

fluoromethyl)phenyl]-;

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-, 1,1-dimethylethyl ester;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methyl-phenyl)-;


Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]- ethyl ester;

Benzoic acid, 2-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-, ethyl ester;

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-; and

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-1,1-dimethylethyl ester.

78. (New): A compound of Formula I:



Formula I

wherein W, X, Y, and Z are C-R<sub>1</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>1</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;

A is O

||

-NH-C-NH ; and






R<sub>1</sub> and R<sub>4</sub> are substituted phenyl, wherein

the substitutions are selected from


- hydrogen

-5-


- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_iOR_{13}$
- $(CH_2)_iSR_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



-6-




and



wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower  
 alky, alkaryl or from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to  
 four hetero atoms as N, O, S.

79. (New): A method for treating a condition  
 advantageously affected by the binding of the compound of  
 Formula I to a CCK receptor in a mammal in need of such  
 treatment comprising providing an effective binding amount  
 of the compound of Formula I:



Formula I

wherein W, X, Y, and Z are  $C-R_3$ ,  $C-R_4$ ,  $C-R_5$ , and  $C-R_6$ ;  
 $R_3-R_6$  are hydrogen;  
 M is oxygen;




-7-

A is  $\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-NH-} \end{array}$




R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>1-4</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>1-4</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



-8-



and




wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower  
 alky, alkaryl or from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to  
 four hetero atoms as N,O,S.

80. (New): A method of reducing gastric acid  
 secretion in a mammal comprising administering an  
 effective gastric acid secretion reducing amount to a  
 mammal in need thereof a compound of Formula I:

-9-




Formula I






wherein W, X, Y, and Z are C-R<sub>1</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;  
 R<sub>1</sub>-R<sub>6</sub> are hydrogen;  
 M is oxygen;  
 A is  $\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-NH} \end{array}$  and  
 R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms;
- (CH<sub>2</sub>)<sub>1</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>1</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



-10-



and




-11-

wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower  
alky, alkaryl of from 7 to 10 carbon atoms; and

$NR_{11}R_{14}$  is also mono or bicyclic ring with one to  
four hetero atoms as N,O,S.

81. (New): A method of reducing anxiety in a mammal,  
comprising administering an effective anxiety reducing  
amount to a mammal in need thereof a compound of Formula  
I:









Formula I

wherein W, X, Y, and Z are C- $R_3$ , C- $R_4$ , C- $R_5$ , and C- $R_6$ ;  
 $R_3$ - $R_6$  are hydrogen;  
M is oxygen;  
A is  $\begin{array}{c} O \\ || \\ -NH-C-NH \end{array}$ ;  
 $R_1$  and  $R_2$  are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_1OR_{13}$
- $(CH_2)_1SR_{11}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

-12-




and

-13-



wherein i and j are independently 0, 1, 2,   
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alkyl, alkaryl or from 7 to 10 carbon atoms; and   
 $NR_{13}R_{14}$  is also mono or bicyclic ring with one to four hetero atoms as N, O, S.

82. (New): A method for treating gastrointestinal ulcers in a mammal comprising administering an effective gastrointestinal ulcer treating amount to a mammal in need thereof a compound of Formula I:



Formula I






wherein W, X, Y, and Z are  $C-R_3$ ,  $C-R_4$ ,  $C-R_5$ , and  $C-R_6$ ;  $R_3-R_6$  are hydrogen; M is oxygen; A is  $\begin{array}{c} O \\ || \\ -NH-C-NH \end{array}$ ; and  $R_1$  and  $R_2$  are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_iOR_{13}$
- $(CH_2)_iSR_{13}$
- trifluoromethyl

-14-


- nitro
- halo
- cyano
- azido
- acetyl



-15-




and



wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower  
 alky, alkaryl or from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to  
 four hetero atoms as N,O,S.

83. (New): A method of treating psychosis in a mammal  
 comprising administering an effective psychosis in a  
 mammal comprising administering an effective psychosis  
 treating amount to a mammal in need thereof a compound of  
 Formula I:




Formula I

wherein W, X, Y, and Z are C- $R_3$ , C- $R_4$ , C- $R_5$ , and C- $R_6$ ;  
 $R_3$ - $R_6$  are hydrogen;  
 M is oxygen;




-16-

A is




 $R_1$  and  $R_2$  are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(\text{CH}_2)_i\text{OR}_{13}$
- $(\text{CH}_2)_i\text{SR}_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



-17-



and




wherein i and j are independently 0, 1, 2,   
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alkyl, alkaryl or from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

84. (New) A method of blocking drug or alcohol withdrawal reaction in a mammal comprising administering an effective withdrawal reaction blocking amount to a mammal in need thereof a compound of Formula I:

-18-



Formula I

wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>;

R<sub>3</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;


A is








and R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>2</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>2</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



-19-



and




-20-

wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower  
alkyl, alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to  
four hetero atoms as N,O,S.

85. (New): A method of treating pain in a mammal  
comprising administering an effective amount to a mammal  
in need thereof a compound of Formula I:



Formula I

wherein wherein W, X, Y, and Z are C-R<sub>1</sub>, C-R<sub>2</sub>, C-R<sub>3</sub>,  
and C-R<sub>4</sub>;

R<sub>1</sub>-R<sub>4</sub> are hydrogen;

M is oxygen;

A is O







    |  
    -NH-C-NH; and

R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_iOR_{13}$
- $(CH_2)_iSR_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl

-21-




and

-22-



wherein i and j are independently 0, 1, 2,   
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower alkyl, alkaryl or from 7 to 10 carbon atoms; and   
 $NR_{13}R_{14}$  is also mono or bicyclic ring with one to four hetero atoms as N, O, S.

86. (New): A method of treating panic in a mammal comprising administering an effective amount to a mammal in need thereof a compound of Formula I:



Formula I






wherein W, X, Y, and Z are C- $R_3$ , C- $R_4$ , C- $R_5$  and C- $R_6$ ;  $R_3$ - $R_6$  are hydrogen; M is oxygen; A is O  
 $\begin{array}{c} | \\ -NH-C-NH \end{array}$ ; and  $R_1$  and  $R_2$  are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_iOR_{11}$
- $(CH_2)_iSR_{11}$
- trifluoromethyl
- nitro

-23-


- halo
- cyano
- azido
- acetyl



-24-




and



wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower  
 alky, alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to  
 four hetero atoms as N,O,S.

87. (New): A method of diagnosis of gastrin-dependent  
 tumors in a mammal, comprising administering to the mammal  
 in need thereof an effective diagnosing amount of a  
 radiolabelled iodo compound of Formula I:







Formula I

wherein W, X, Y, and Z are C- $R_3$ , C- $R_4$ , C- $R_5$ , and C- $R_6$ ;  
 $R_3$ - $R_6$  are hydrogen;  
 M is oxygen;  
 A is O  
 $\begin{array}{c} | \\ -NH-C-NH \end{array}$ ; and



-25-

$R_1$  and  $R_2$  are substituted phenyl, wherein the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_iOR_{13}$
- $(CH_2)_iSR_{11}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



-26-



and




wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower  
alky, alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to  
four hetero atoms as N,O,S.

88. (New): A pharmaceutical composition comprising an effective therapeutical amount of the compound of Formula I and a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier and unit dosage form wherein the therapeutic indication is selected from the group consisting of an appetite suppressant, a gasteric acid secretion reducing agent, an anxiety reducing agent, a gasterointestinal ulser treating agent, a phycosis treating agent, a with drawal reaction blocking agent, a pain treatment agent, an agent for treating or preventing panic, an agent for treating gasterin dependent tumors

-27-



Formula I

Wherein W, X, Y, and Z are C-R<sub>3</sub>, C-R<sub>4</sub>, C-R<sub>5</sub>, and C-R<sub>6</sub>; R<sub>1</sub>-R<sub>6</sub> are hydrogen;

M is oxygen;


A is O

|  
-NH-C-NH;






and R<sub>1</sub> and R<sub>2</sub> are substituted phenyl, wherein

the substitutions are selected from


- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH<sub>2</sub>)<sub>2</sub>OR<sub>13</sub>
- (CH<sub>2</sub>)<sub>2</sub>SR<sub>13</sub>
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



-28-



and



-29-

wherein i and j are independently 0, 1, 2,  
 $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$  are each independently hydrogen, lower  
alkyl, alkaryl or from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$  is also mono or bicyclic ring with one to  
four hetero atoms as N,O,S; provided that  $R_2$  is  
monosubstituted phenyl.